Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kite long-term follow-up study after genetically modified cell therapy
MOH_2022-08-21_010606Phase 2Not yet recruiting
- Sponsor
- Kite Pharma
- Start
- Aug 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in hematopoietic malignancies and Nonhematologic neoplasms, sponsored by Kite Pharma. Primary endpoint: Long-term safety follow-up. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
hematopoietic malignanciesNonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2022-08-21_010606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-21_010606.